Photo - Mobio Interactive
play_arrow
View
59595

Mobio Interactive

Singapore
Market: Medicine, Other, Artificial Intelligence, Mobile applications
Stage of the project: Operating business

Date of last change: 16.02.2023
Go to the owner's profile
5
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

Precision psychiatry at scale.

Current Status

Globally significant milestones: 1) world-leading accuracy of stress measurement from mobile selfies, 2) first organisation to show app-based meditation can outperform placebo, 3) objective personalisation delivering 2.5x efficacy - proving that precision psychiatry can be scaled. The company’s intervention treating cancer-related post traumatic stress is expected to receive regulatory clearance by the FDA, Health Canada and Singapore’s HSA in 2023.

Problem or Opportunity

Mental healthcare has two massive challenges: 1) Meeting the large and increasing demand for care, and 2) Identifying what treatment is best for each patient.

Solution (product or service)

Mobio Interactive has invented a revolutionary new approach that solves both mental healthcare challenges. By delivering clinically validated therapy on the phone asynchronously and on-demand, the company has solved the first challenge. Meanwhile, they solve the second challenge by quantifying the efficacy of therapy in real-time with computer vision and AI without a wearable. The result is precision psychiatry at scale for the first time in history.

Business model

We are adopting the regulatory-approved and payor-reimbursed pharmaceutical model to digital therapeutics, leading to full integration of our software as medicine into the healthcare economy.

To accelerate and de-risk this business objective, we are simultaneously commercialising our technology via routes that do not require regulatory approval (Class I SaMD). This “near-term” approach has the added benefit of generating immediate revenues, while establishing the networks and collaborations needed to command market leading status following regulatory approval of Class II SaMD interventions.

Incubation/Acceleration programs accomplishment

MedTech Innovator APAC, H+ Digital Health Innovation Programme, BioFM Incubator, Ontario Bioscience Innovation Organization Health to Business Bridge Programme, Canadian Technology Accelerator, BioMedical Zone, Vienna Start-up Package, Chinaccelerator
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility391
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Product Video
Presentation